QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.49 (-3.35%)
BABA   72.33 (+1.17%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.22%)
MU   73.65 (+0.71%)
CGC   0.72 (+3.57%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.82 (+0.44%)
PFE   28.63 (-0.56%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.49 (-3.35%)
BABA   72.33 (+1.17%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.22%)
MU   73.65 (+0.71%)
CGC   0.72 (+3.57%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.82 (+0.44%)
PFE   28.63 (-0.56%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.49 (-3.35%)
BABA   72.33 (+1.17%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.22%)
MU   73.65 (+0.71%)
CGC   0.72 (+3.57%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.82 (+0.44%)
PFE   28.63 (-0.56%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)
QQQ   390.43 (+1.40%)
AAPL   194.27 (+1.01%)
MSFT   370.95 (+0.58%)
META   326.59 (+2.88%)
GOOGL   136.93 (+5.31%)
AMZN   146.88 (+1.63%)
TSLA   242.64 (+1.37%)
NVDA   465.96 (+2.40%)
NIO   7.49 (-3.35%)
BABA   72.33 (+1.17%)
AMD   128.37 (+9.89%)
T   17.09 (+0.89%)
F   10.82 (+1.22%)
MU   73.65 (+0.71%)
CGC   0.72 (+3.57%)
GE   119.48 (-0.28%)
DIS   92.35 (+0.93%)
AMC   6.82 (+0.44%)
PFE   28.63 (-0.56%)
PYPL   58.48 (-1.76%)
XOM   98.42 (-0.70%)

Cyclo Therapeutics Stock Price, News & Analysis (NASDAQ:CYTH)

$1.32
+0.01 (+0.76%)
(As of 05:28 PM ET)
Compare
Today's Range
$1.29
$1.49
50-Day Range
$0.93
$1.69
52-Week Range
$0.67
$2.57
Volume
38,195 shs
Average Volume
92,995 shs
Market Capitalization
$30.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Cyclo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
198.5% Upside
$4.00 Price Target
Short Interest
Bearish
2.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

756th out of 958 stocks

Biological Products, Except Diagnostic Industry

113th out of 143 stocks


CYTH stock logo

About Cyclo Therapeutics Stock (NASDAQ:CYTH)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

CYTH Stock Price History

CYTH Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Cyclo Therapeutics reports Q3 results
WISH, REAL and PIXY among mid-day movers
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
CYTH Cyclo Therapeutics, Inc.
See More Headlines
Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/17/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/18/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTH
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+198.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,450,000.00
Net Margins
-2,037.29%
Pretax Margin
-2,037.19%

Debt

Sales & Book Value

Annual Sales
$951,809.00
Book Value
$0.07 per share

Miscellaneous

Free Float
15,962,000
Market Cap
$30.46 million
Optionable
Not Optionable
Beta
-0.04
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















CYTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclo Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTH shares.
View CYTH analyst ratings
or view top-rated stocks.

What is Cyclo Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 1-year target prices for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 198.5% from the stock's current price.
View analysts price targets for CYTH
or view top-rated stocks among Wall Street analysts.

How have CYTH shares performed in 2023?

Cyclo Therapeutics' stock was trading at $1.42 on January 1st, 2023. Since then, CYTH shares have decreased by 5.6% and is now trading at $1.34.
View the best growth stocks for 2023 here
.

Are investors shorting Cyclo Therapeutics?

Cyclo Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 223,000 shares, an increase of 76.4% from the October 31st total of 126,400 shares. Based on an average daily volume of 55,400 shares, the short-interest ratio is currently 4.0 days. Approximately 2.6% of the company's stock are short sold.
View Cyclo Therapeutics' Short Interest
.

When is Cyclo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our CYTH earnings forecast
.

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.34. The business earned $0.19 million during the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 1,706.53% and a negative net margin of 2,037.29%.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTH) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -